We are live on ! Find out more
ACA

Avoro Capital Advisors Portfolio holdings

AUM $10.2B
1-Year Est. Return 149.19%
This Fund
S&P 500
This Quarter Est. Return
+82.63%
1 Year Est. Return
+149.19%
3 Year Est. Return
+425.03%
5 Year Est. Return
+775.33%
10 Year Est. Return
+45,729.2%
AUM
$5.06B
AUM Growth
+$2.1B
Cap. Flow
+$394M
Cap. Flow %
7.79%
Top 10 Hldgs %
66.41%
Holding
52
New
9
Increased
18
Reduced
13
Closed
7

Top Buys

Rank Stock Value
1
MRSN
Mersana Therapeutics
MRSN
+$88.8M
2
ADAP
Adaptimmune Therapeutics
ADAP
+$62.8M
3
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$61M
4
ARNA
Arena Pharmaceuticals Inc
ARNA
+$52.3M
5
IMMU
Immunomedics Inc
IMMU
+$51.2M

Top Sells

Rank Stock Value
1
PTCT icon
PTC Therapeutics
PTCT
+$43M
2
SAGE
Sage Therapeutics
SAGE
+$28.7M
3
TCDA
Tricida, Inc. Common Stock
TCDA
+$20.8M
4
ZGNX
Zogenix, Inc.
ZGNX
+$15.2M
5
ATNX
Athenex, Inc. Common Stock
ATNX
+$10.8M

Sector Composition

Rank Sector Weight
1 Healthcare 80.25%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TGTX icon
51
TG Therapeutics
TGTX
$7.59B
– –
-800,000
Closed -$7.87M
IMGN
52
DELISTED
Immunogen Inc
IMGN
– –
-1,900,000
Closed -$6.48M
1 2
3

Similar funds

IIM
INTECH Investment Management West Palm Beach, Florida $10.2B AUM 28.14% 1-Year Est. Return
GI
GAMCO Investors Greenwich, Connecticut $10.2B AUM 30.27% 1-Year Est. Return
VPIM
Vanguard Personalized Indexing Management Oakland, California $10.2B AUM 34.45% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
OIA
OneDigital Investment Advisors Overland Park, Kansas $10.2B AUM 16.58% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
HRCM
Hood River Capital Management Palm Beach Gardens, Florida $9.98B AUM 145.42% 1-Year Est. Return
WAM
Wolverine Asset Management Chicago, Illinois $10.4B AUM 4.78% 1-Year Est. Return

Avoro Capital Advisors's Q2 2020 Portfolio in Review

As of Q2 2020, Avoro Capital Advisors held 52 positions worth $5.06B, up 71% from $2.96B the previous quarter. Its ten largest holdings account for 66% of the portfolio.

Avoro Capital Advisors deployed $394M of net new capital in Q2 2020, opening 9 new positions and adding to 18 existing holdings. Its largest new stake was Mersana Therapeutics: 260,000 shares worth $152M.

By sector, the portfolio is most concentrated in Healthcare at 80% of assets, down from 88% a quarter earlier.

On the sell side, the largest reduction was PTC Therapeutics, an estimated $43M trimmed.

  • Avoro Capital Advisors's largest Q2 2020 buy was Mersana Therapeutics: 260,000 shares worth $152M.
  • Avoro Capital Advisors added most to Horizon Therapeutics Public Limited Company Ordinary Shares in Q2 2020, an estimated $61M increase.
  • Avoro Capital Advisors's biggest Q2 2020 reduction was PTC Therapeutics, cutting an estimated $43M.
  • Avoro Capital Advisors fully exited Sage Therapeutics in Q2 2020, selling an estimated $28.7M.
  • Avoro Capital Advisors's ten largest holdings make up 66% of its $5.06B portfolio in Q2 2020.
  • Avoro Capital Advisors opened 9 new positions and closed 7 in Q2 2020.
  • Avoro Capital Advisors's portfolio value rose 71% quarter-over-quarter to $5.06B.

Based on Avoro Capital Advisors's 13F filing for Q2 2020, filed 14 Aug 2020.